Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia.

ABSTRACT:

Introduction

We explored what combination of blood-based biomarkers (amyloid beta [Aβ]_1-42/1-40, phosphorylated tau [p-tau]181, neurofilament light [NfL], glial fibrillary acidic protein [GFAP]) differentiates Alzheimer's disease (AD) dementia, frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB).

Methods

We measured the biomarkers with Simoa in two separate cohorts (n = 160 and n = 152). In one cohort, Aβ_1-42/1-40 was also measured with mass spectrometry (MS). We assessed the differential diagnostic value of the markers, by logistic regression with Wald's backward selection.

Results

MS and Simoa Aβ_1-42/1-40 similarly differentiated AD from controls. The Simoa panel that optimally differentiated AD from FTD consisted of N

SUBMITTER: Thijssen EH 

PROVIDER: S-EPMC9107685 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature